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The improved accuracy in tumor identification with FDG-PET has led to its increased uti-
lization in target volume delineation for radiotherapy treatment planning in the treatment
of lung cancer. However, PET/CT has constantly been influenced by respiratory motion-
related image degradation, which is especially prominent for small lung tumors in the
peri-diaphragmatic regions of the thorax. Here, we describe the current findings on respi-
ratory motion-related image degradation in PET/CT, which may bring uncertainties to target
volume delineation for image guided radiotherapy (IGRT) for lung cancer. Furthermore, we
describe the evidence suggesting 4D PET/CT to be one strategy to minimize the impact
of respiratory motion-related image degradation on tumor target delineation for thoracic
IGRT. This, in our opinion, warrants further investigation in future IGRT-based lung cancer
trials.
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INTRODUCTION
In recent years, 18F fluorodeoxyglucose positron emission tomog-
raphy/computed tomography (FDG-PET/CT) is increasingly used
in the delineation of gross tumor for thoracic radiotherapy plan-
ning purposes (1, 2). As of now, multiple methods of PET-based
tumor volume delineation exist and are being used in clinical
practice (3, 4). Although PET/CT may potentially improve tumor
delineation, quality and FDG uptake quantification of the PET/CT
image are often impaired by respiratory motion. This may lead
to decreased accuracy in lung cancer target volume delineation,
which decreases the efficacy of thoracic image guided radiother-
apy (IGRT), as the uttermost accuracy in tumor localization is
desired in IGRT to achieve the most optimal tumor control and
normal tissue sparing at the same time. The main cause of this
limitation is the difference in the speed of imaging between PET
and CT.
In the following sections, the respiratory motion artifacts in
PET/CT imaging; and four-dimensional (4D, which accounts for
changes in time) PET/CT as a potential strategy to reduce respira-
tory motion artifacts in the PET/CT imaging of lung cancer will
be discussed as this may potentially improve the target volume
delineation for thoracic IGRT.
RESPIRATION MOTION ARTIFACTS IN FDG-PET/CT
Computed tomography and positron emission tomography imag-
ing are done at different speeds. While a CT scan can be completed
in seconds, the PET is usually done through a sequence of fields
of view (FOV) in a matter of several minutes per FOV. As a result,
the CT image may capture the lung tumor in a segment of the
respiratory cycle only, while the PET image tends to represent an
average of the tumor position over several respiratory cycles. This
often leads to blurring and/or misrepresentation of the extent of
the gross tumor in the registered PET/CT images of the thorax
(Figure 1). At the same time, the pattern of FDG uptake intensity
within the gross tumor can be changed by respiration, leading to
a decrease in the max SUV of the tumor.
Respiratory motion artifacts on PET/CT have been well
described in a series of studies (Table 1). In one study, differ-
ent anatomical points between the apices and the diaphragmatic
domes of the lungs on PET/CTs were identified and matched (5).
For each patient, the PET was registered to CTs obtained during
maximum inspiration, maximum expiration, free breathing, and
normal expiration. Prominent mismatch between FDG-PET and
CT was found during maximum inspiration and maximum expi-
ration, and the best PET/CT co-registration occurred when the CT
was obtained during normal expiration (5). Mismatch between
PET and CT was most prominent at the diaphragmatic dome. On
average, it was 0.4 mm with the CT taken during normal expira-
tion, but 44.4 mm with the CT taken during maximum inspiration
(p= 0.001). This has a direct influence on image registration for
tumor in PET/CT.
In another study, the accuracy of PET and CT registration for
non-small cell lung cancer was investigated with CT obtained dur-
ing shallow breathing or normal expiration (6). The most promi-
nent incongruence of gross tumor on CT and on PET was observed
at the periphery and the base of the lungs (0.5–14.7, 2.9–11.3 mm,
respectively). Much less incongruence was observed in the central
and apical regions of the lungs (1.7–5.4, 0.7–5.9 mm, respectively)
(p< 0.0001). In this study, normal expiration appears to be better
than shallow breathing for PET/CT matching (p= 0.024).
Errors in spatial registration of lung lesions on PET/CT were
also observed in free-breathing (FB) patients by Cohade et al. (7).
www.frontiersin.org August 2014 | Volume 4 | Article 205 | 1
Chi and Nguyen 4D-PET/CT-based IGRT
FIGURE 1 | Misalignment of a recurrent squamous cell carcinoma between free-breathing PET and CT is demonstrated. The superior portion of the PET
avid tumor does not correspond to any anatomically visible tumor on CT.
Table 1 | Motion artifacts observed in FDG-PET/CT.
Artifacts observed
Goerres et al. (5) Mismatch of the diaphragmatic dome between PET and CT was 44.4±25.5 mm between free-breathing PET and CT obtained
during maximum inspiration. It ranged between 8.7 and 82.9 mm
Goerres et al. (6) Mismatch of NSCLC lesions was most prominent at the lung periphery:
Breathing: 6.5±3.6 mm (3.4–14.7 mm)
Breath hold: 6±2.9 mm (0.5–11.4 mm)
And the lung base:
Breathing: 8.2±1 mm (7.2–9.8 mm)
Breath hold: 6.2±2.6 mm (2.9–11.3 mm)
Cohade et al. (7) Misregistration of free-breathing PET and CT was 7.55±4.73 mm
Lower lungs: 10.2±6.55 mm
Upper lungs: 6.67±4.28 mm
Left lung: 8.33±5.05 mm
Right lung: 6.25±3.92 mm
Osman et al. (8) Six patients with liver metastases at the liver dome mislocalized to the right lower lobe of the lung on free-breathing PET
Goerres et al. (9) PET attenuation by CT taken during maximum inspiration led to a decrease in FDG concentration in lung tumors by 42±12%
when compared to that attenuated by CT taken during maximum expiration
Erdi et al. (10) Tumor displacement of 6.4–24.7 mm, and tumor maximum SUV reduction of 6–24% were observed between maximum
inspiration and expiration
Nehmeh et al. (11) 4D PET can led to a 28% reduction in tumor volume and 56.5% increase in tumor maximum SUV in a patient when compared
to free-breathing PET/CT
Liu et al. (12) Diaphragmatic motion of 11 mm can cause maximum SUV underestimation of 28% and tumor volume overestimation of 130%
on average for 1 cm lung lesions
In their study, the distance between the center of lung lesions
defined on PET and CT was 7.55 mm on average, which tended
to be more pronounced in lower lobe tumors. As shown in these
studies, errors in PET/CT registration may become significant in
the peri-diaphragmatic region, which can lead to mislocalization
of a tumor into an adjacent organ in extreme cases (8).
In addition to image registration mismatch, respiratory motion
can also lead to a decrease in measured FDG concentration in lung
tumors, which may be further confounded by other factors, such
as the body size, blood glucose concentration, uptake time allowed,
interscanner variability, and image reconstruction parameters (9,
13). This is well described by Erdi et al. when PET was regis-
tered with respiration-corrected CT over 10 phases (10). Between
maximum inspiration and expiration, lesion displacement of 6.4–
24.7 mm was observed on 4D CT, which correlated with decrease
in tumor maximum SUV of 6–24% between end inspiration and
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end expiration. The reduction of FDG uptake intensity observed
is due to a redistribution of FDG activity concentration over the
range of respiratory motion, which leads to a drop in maximum
activity concentration within the tumor (11). As FDG uptake dis-
tribution within a tumor is altered, the shape of the gross tumor
may also be altered, leading to an increase in tumor size on PET.
The respiratory motion induced change in FDG uptake inten-
sity is further demonstrated in an analysis of routine PET/CT
studies in correlation with over 1000 respiratory traces that is
validated in a phantom study (12). In this study, a mean max-
imum SUV underestimation of 28% and mean lesion volume
overestimation of 130% in PET/CT images of 1 cm lesions were
observed when respiratory motion at the diaphragm is 11 mm.
The underestimation of FDG intensity appears to be proportional
to respiratory motion amplitude.
In the same study, PET/CT mismatch-related FDG intensity
overestimation for lower lobe lung lesions located close to the
dome of the liver was also reported. The fluctuation in activity con-
centration within the tumor may potentially decrease the quality
and capability of tumor imaging, which may affect the appropriate
delineation of the gross tumor volume (GTV) during radiotherapy
treatment planning.
Various strategies have been proposed to reduce respiratory
motion artifacts in PET/CT. Among them, PET registered with
a respiratory motion averaged CT has been proposed by Chi
et al. (14). Motion averaged CT is conducted following routine
PET/CT in 229 lung cancer patients in this study. Image align-
ment and tumor quantification were analyzed in 216 of these
patients. Image misalignment was observed in 68% of the 216 rou-
tine PET/CTs, which was completely removed (86.21%) or reduced
(13.79%) with PET and motion averaged CT registration. Among
120 PET/CTs in which the GTV can be delineated, alignment cor-
rection with motion averaged CT was associated with changes in
the maximum SUV and GTV of up to 73 and 1950% between
PET registered with regular CT and PET registered with motion
averaged CT. The largest variation was observed in small lesions
<50 cm3 in the vicinity of the diaphragm. Thus,demonstrating the
potential for PET attenuated/registered with motion averaged CT
to enhance tumor quantification on PET, which is also suggested
in a study of 80 patients with NSCLC by Cheng et al. (15).
An alternative approach to reducing respiratory motion-
related PET/CT image degradation is PET/CT acquisition through
repeated imaging during breath holding (16, 17). However, this
method may be limited by patient compliance if used for tumor
volume delineation in patients with NSCLC due to their poor
pulmonary function.
On the other hand, such image degradation can be more easily
reduced by the generation of a respiratory motion corrected or 4D
PET/CT during which the PET data are acquired in synchroniza-
tion with respiratory motion, which can also minimize the poor
image quality of PET/motion averaged CT in the vicinity of soft
tissue, such as the diaphragm and the chest wall (11, 18, 19). 4D
PET/CT is done through tracking an external tracer block that is
placed on a patient’s abdomen at the time of image acquisition
as observed in 4D CT. Through 4D PET/CT imaging, prominent
increase in FDG intensity of the tumor and reduction of tumor size
due to decreased smearing effect have been observed (11, 20–22).
This may potentially increase the accuracy of GTV delineation on
FDG-PET/CT and decrease the amount of normal tissue included
in the GTV. As a result, increased accuracy for tumor localiza-
tion and radiation dose escalation with IGRT for NSCLC may be
possible.
4D FDG-PET IN TARGET VOLUME DELINEATION FOR IGRT
A very high degree of accuracy is required in the target vol-
ume delineation to optimize accurate tumor localization and
maximal margin reduction in the delivery of image guided,
intensity-modulated radiotherapy (IMRT) for lung cancer. Respi-
ratory motion-related image degradation observed in FB PET/CT
may have an impact on the accuracy of target volume delin-
eation for sophisticated treatments, such as IGRT. In the plan-
ning of stereotactic ablative radiotherapy (SABR) for early-stage
NSCLC, FB PET-target volumes often do not entirely encompass
tumor motion, as FB-PET tumor volumes are often smaller than
ITVs generated from the maximum intensity projections (MIP)
obtained from 4D CT (23). Thus, target volumes delineated on FB-
PET may increase the risk of geometric misses. This is especially
problematic for image guided SABR, because of the high reliance
on accurate tumor localization and the potential consequences of
severe toxicity due to such misses. However, this problem may be
corrected by 4D PET/CT imaging (22).
With the utilization of 4D FDG-PET or PET/CT, the most PET
active subvolumes within the tumor may be more consistently
identified for dose painting (24). In addition, missing disease
undetectable on FB PET due to image degradation may be pre-
vented with 4D PET/CT in the planning of thoracic IGRT in order
to achieve the maximal TCP (25). 4D PET MIP for ITV delineation
was described in detail by Lam et al. (18). ITV generated from 4D
PET MIP was found to better correlate with that generated from
4D CT MIP than FB-PET-based ITV in this study. Furthermore,
better definition of the extent of tumor in the vicinity of mobile
structures, such as the diaphragm, the heart, and the chest wall
with 4D PET was demonstrated, which can potentially improve
the accuracy of tumor target definition and the sparing of normal
tissue that is of similar density to the tumor.
Similarly, 4D PET-based ITV generation may improve the
identification of tumor motion in the hilar and mediastinal
regions over CT alone. Respiratory motion has been known
to affect mediastinal and hilar lymph nodes (26). However,
the similar tissue density between nodal disease and surround-
ing normal tissue in the mediastinal region may pose a chal-
lenge to ITV definition based on 4D CT alone. In a com-
parison of ITV generation based on 3D PET and 4D PET,
a 1.3 cm expansion was required for ITV3D to include 91%
of the nodal disease (27). Further analysis of the ITV3D with
4D PET demonstrated the inclusion of 45± 34 cm3 non-PET-
avid tissues in the 3D PET volume. Therefore, 4D PET-based
nodal ITV may further improve the accuracy of nodal disease
definition, leading to the sparing of additional normal tissue
adjacent to regional nodal disease. This may further improve
the therapeutic ratio, especially with IGRT in the treatment of
lung cancer.
The current evidence, described above, suggests that target vol-
ume delineation based on 4D PET/CT information may be the best
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approach currently available for the delineation of tumor volumes
for lung cancer. It warrants further investigation in future prospec-
tive studies, especially in the setting of dose escalation. In our
opinion, its use in the clinical setting whenever possible is strongly
encouraged, as it may improve patient treatment outcome in the
setting of IGRT for lung cancer.
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